Balyasny Asset Management
CRVS icon

Balyasny Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Balyasny Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,031
Closed -$193K – 2983
2025
Q4 		$193K Sell
25,031
-541
-2% -$4.27K ﹤0.01% 2891
2025
Q3 		$188K Buy
+25,572
New +$131K ﹤0.01% 2736
2025
Q2 		– Sell
-57,827
Closed -$184K – 2904
2025
Q1 		$184K Buy
57,827
+9,492
+20% +$44.7K ﹤0.01% 2606
2024
Q4 		$259K Buy
+48,335
New +$361K ﹤0.01% 2451

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Balyasny Asset Management's CRVS Position: Q1 2026 in Review

Balyasny Asset Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 25,031 shares — an estimated $193K sold.

Balyasny Asset Management first reported a position in CRVS in Q4 2024 and held it in 4 quarters. The position peaked at $259K in Q4 2024. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Balyasny Asset Management reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 25,031 Corvus Pharmaceuticals shares in Q1 2026, an estimated $193K.
  • Balyasny Asset Management first reported a position in Corvus Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Balyasny Asset Management's Corvus Pharmaceuticals position peaked at $259K in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.